Complete remission on 18-fluorodeoxyglucose positron emission tomography/computed tomography after nivolumab treatment in a patient with indolent hodgkin lymphoma
Translational Cancer Research, cilt.5, sa.3, ss.320-323, 2016 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 5 Sayı: 3
- Basım Tarihi: 2016
- Doi Numarası: 10.21037/tcr.2016.06.02
- Dergi Adı: Translational Cancer Research
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.320-323
- Anahtar Kelimeler: Refractory Hodgkin lymphoma, nivolumab, 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Most patients with Hodgkin lymphoma (HL) get a remission after induction chemotherapy with or without radiation therapy (RT). However, relapse rates range from 10-20% in cases of stage I-II disease to 30-40% in patients with more stage III-IV disease. In addition, approximately 10-15% of patients suffer disease progression after a partial initial response. Nivolumab is an immunotherapeutic antineoplastic developed as a totally human immunoglobulin G4 (IgG4) monoclonal antibody against programmed death-1 (PD-1), an immune checkpoint inhibitor that negatively controls T-cell proliferation and functions. Intravenous administration of nivolumab was approved for the treatment of unresectable malignant melanoma in 2014 in Japan. Phase 1 or 2 studies in certain malignities including HL has been going on. Herein, we present a patient with relapsed/refractory HL not responded to multiple protocols, but successfully treated by nivolumab as depicted on 18-fluorodeoxyglucose positron emission tomography/ computed tomography (FDG-PET/CT).